This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Campbell, R. K. Articles by Miller, S. PubMed PubMed Citation Articles by Campbell, R. K. Articles by Miller, S. Social Bookmarking                         What's this?

New Therapeutic Horizons

Mapping the Future of Glycemic Control With Incretin-based Therapy

From Washington State University College of Pharmacy, Pullman, Washington (Mr Campbell), and Med-IQ, Baltimore, Maryland (Ms Campbell).

Correspondence to R. Keith Campbell, RPh, MBA, FASHP, CDE, Washington State University College of Pharmacy, Pullman, Washington (rkcamp{at}wsu.edu).

Purpose

More than 24 million adults and children in the United States are living with diabetes, and the vast majority of those individuals have type 2 diabetes. The clinical benefits of good glycemic control have been well established. Most patients eventually require the use of multiple hyperglycemic drugs in combination to approach or achieve the American Diabetes Association's recommended target A1C value of 7%. The role of incretin-based therapies for both glycemic control and β-cell protection has become an area of intense interest and development. Although current practice guidelines do not include specific recommendations about when and how to incorporate incretin-based agents, a consensus statement published by the American Diabetes Association/European Association for the Study of Diabetes suggests the addition of a glucagon-like peptide-1 (GLP-1) agonist for patients not at goal A1C with metformin and lifestyle changes. The goal of this article is to review this class of agents, discuss their role in the treatment of type 2 diabetes, and address the practical aspects of integrating incretin-based agents into the management of patients with diabetes.

Conclusion

Currently, 3 incretin-based therapies are available and widely used in clinical practice. Several more agents are either under review by the Food and Drug Administration (FDA) or are in the very late stages of development. For diabetes educators trying to help their patients understand the differences among their antidiabetic medications, a comprehensive understanding of these agents and their role in therapy is imperative.

The Diabetes Educator, Vol. 35, No. 5, 731-747 (2009)
DOI: 10.1177/0145721709342900


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?